UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043942
Receipt number R000050167
Scientific Title Explore research for osimertinib sensitivity in EGFR mutated non-small cell lung cancer; prospective observation study
Date of disclosure of the study information 2021/04/15
Last modified on 2022/10/15 14:27:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Explore research for osimertinib sensitivity in EGFR mutated non-small cell lung cancer; prospective observation study

Acronym

Explore research for osimertinib sensitivity in EGFR mutated non-small cell lung cancer; prospective observation study

Scientific Title

Explore research for osimertinib sensitivity in EGFR mutated non-small cell lung cancer; prospective observation study

Scientific Title:Acronym

Explore research for osimertinib sensitivity in EGFR mutated non-small cell lung cancer; prospective observation study

Region

Japan


Condition

Condition

EGFR mutated non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To explore clinical factors that may be candidates for determining susceptibility to osimertinib in EGFR mutated NSCLC patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Association between treatment response with osimertinib treatment and patients background

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Patients with evaluable disease by RECIST (version 1.1) before osimertinib administration
2) NSCLC patients with EGFR active mutation
3) Patients with formalin-fixed, paraffin-embedded blocks that do not interfere with pathological diagnosis and for whom consent for their use can be obtained from the patient.

Key exclusion criteria

Patients judged as inappropriate by the physician in charge

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Tadaaki
Middle name
Last name Yamada

Organization

Kyoto Prefectural University of Medicine

Division name

Pulmonary Medicine

Zip code

6028566

Address

465, Kajii-cho, Kamigyo-ku, Kyoto

TEL

075-251-5513

Email

tayamada@koto.kpu-m.ac.jp


Public contact

Name of contact person

1st name Akihiro
Middle name
Last name Yoshimura

Organization

Kyoto Prefectural University of Medicine

Division name

Pulmonary Medicine

Zip code

6028566

Address

465, Kajii-cho, Kamigyo-ku, Kyoto

TEL

0752515513

Homepage URL


Email

aki-y@koto.kpu-m.ac.jp


Sponsor or person

Institute

Kyoto Prefectural University of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

1. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
2. Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medicine and Dental Hospital, Niigata, Japan
3. Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
4. Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
5. Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan.
6. Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
7. Department of Medical Oncology, Fukuchiyama City Hospital, Kyoto, Japan.
8. Department of Respiratory Medicine, Otsu City Hospital, Shiga, Japan
9. Department of Respiratory Medicine, Juntendo University, Tokyo, Japan
10. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
11. Department of Respiratory Medicine, Fujita Health University School of Medicine, Aichi, Japan
12. Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
13. Department of Thoracic Oncology, Osaka International Cancer Institution, Osaka, Japan

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto Prefectural University of Medicine

Address

465, Kajii-cho, Kamigyo-ku, Kyoto,

Tel

075-251-5513

Email

aki-y@koto.kpu-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 04 Month 15 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled

100

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 08 Month 02 Day

Date of IRB

2018 Year 08 Month 23 Day

Anticipated trial start date

2018 Year 09 Month 01 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry

2023 Year 03 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2021 Year 04 Month 15 Day

Last modified on

2022 Year 10 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050167


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name